ライフサイエンスコーパス: clinical study

1 Retrospective, nonrandomized, comparative clinical study.

2 t during walking in a multi-week exploratory clinical study.

3 ospective, randomized, controlled fellow eye clinical study.

4 Cross-sectional observational clinical study.

5 Multicenter, retrospective, nonrandomized clinical study.

6 Single-arm, open-label, multicenter clinical study.

7 Post-hoc analysis of a prospective clinical study.

8 aring T cells in multiple compartments for a clinical study.

9 Prospective, cross-sectional clinical study.

10 andomized, double-masked, placebo-controlled clinical study.

11 ve sepsis outcomes in animal studies and one clinical study.

12 ch is currently being evaluated in a phase I clinical study.

13 1 is currently being investigated in a human clinical study.

14 ries including national surveys and relevant clinical studies.

15 cations for the design and implementation of clinical studies.

16 ds the goal of scale-up for large animal pre-clinical studies.

17 slation of findings from disease models into clinical studies.

18 hibitors are being tested in preclinical and clinical studies.

19 NI, as well as antiproliferative activity in clinical studies.

20 oantigens paves the way to their use in (pre)clinical studies.

21 ial biomarker of target engagement for early clinical studies.

22 to the disputed efficacy assessed in various clinical studies.

23 C5a inhibition is currently being tested in clinical studies.

24 dies, as well as experimental psychology and clinical studies.

25 anasal (IN) route is the preferred method in clinical studies.

26 influenza vaccines cannot be determined from clinical studies.

27 or 11 led to its evaluation in several human clinical studies.

28 hence, CyG qualifies as imaging material for clinical studies.

29 -1 envelope spike in quantities suitable for clinical studies.

30 infiltration has also been assessed in many clinical studies.

31 nvironments in experimental cell biology and clinical studies.

32 is the gap between current pre-clinical and clinical studies.

33 vidence of its efficacy from preclinical and clinical studies.

34 , and (c) representative sample selection in clinical studies.

35 and immunogenicity in multiple HIV-1 phase I clinical studies.

36 rVSV vector that has demonstrated safety in clinical studies.

37 ecause of the inconsistent findings from the clinical studies.

38 areful scrutiny in ongoing basic science and clinical studies.

39 n be used in clinical practice as well as in clinical studies.

40 of drug delivery systems in preclinical and clinical studies.

41 r design developed in prior pre-clinical and clinical studies.

42 roach can be potentially used in prospective clinical studies.

43 th cognitive impairment and brain changes in clinical studies.

44 after spinal cord injury (SCI) in animal and clinical studies.

45 e pharmacokinetic properties of metformin in clinical studies.

46 inical practice and conflicting results from clinical studies.

47 alyses published as there are well-conducted clinical studies.

48 s for in vivo animal retinal imaging and pre-clinical studies.

49 lications, all of which reported exploratory clinical studies.

50 we show in preclinical and proof-of-concept clinical studies.

51 tor 2 (PF-06263276), which was advanced into clinical studies.

52 ll of which are being evaluated in phase 1-3 clinical studies.

53 ity, and we are currently awaiting the first clinical studies.

54 ted and variable, thus impeding research and clinical studies.

55 linical studies to complementary findings in clinical studies.

56 ples of their application in preclinical and clinical studies.

57 r novel hypotheses in future preclinical and clinical studies.

58 ral history of PBC was informed by published clinical studies.

59 ted therapeutically in preclinical and early clinical studies.

60 es the question of the relevant endpoints in clinical studies.

61 f the quality of vaccine-induced immunity in clinical studies.

62 For the clinical study, 211 samples from 10 proven/probable inva

63 y healthy volunteers (n = 47) in 4 different clinical studies-3 with a randomized, double-masked cros

64 piperaquine concentration-time data from 11 clinical studies (8,776 samples from 728 individuals) in

65 th SCD and warrant a large-scale prospective clinical study addressing optimal IVF management during

66 nd malaria coepidemic in sub-Saharan Africa, clinical studies aimed at determining the optimum durati

67 Comprehensive pre-clinical studies aimed at establishing effectiveness of

68 F datasets, which are increasingly common in clinical studies and cancer studies that monitor various

69 To characterize the quality of the clinical studies and data (strength of evidence) used to

70 ealth record documentation, harmonization of clinical studies and database development, and clinical

71 nd analyze raw source data from separate pre-clinical studies and evaluated interactions between four

72 r, E4 was recently evaluated in phase 1 to 2 clinical studies and found to act as an oral contracepti

73 However, clinical studies and insights from model organisms have

74 n and AD has long been appreciated, emerging clinical studies and insights from the basic neuroscienc

75 hese observations, which are usually made in clinical studies and intervention trials; and gives exam

76 Barrett's esophagus, based on findings from clinical studies and mouse models of disease.

77 -2 was found to be well-tolerated in phase 1 clinical studies and represents a potential new treatmen

78 ainst clinical Gram-negative bacteria during clinical studies and routine patient care.

79 malignancies with special focus on conducted clinical studies and strategies to improve their efficac

80 anti-myostatin approaches in several of the clinical studies and the apparent contradictory results

81 Additional clinical studies and trials using immunotherapeutic or n

82 d race-adjusted SIRs using data from a large clinical study and the SEER database, we found that IFX

83 review of preclinical studies, retrospective clinical studies, and clinical trials, we examined the b

84 Clinical studies are beginning to define these factors a

85 st expansions in animal models, results from clinical studies are controversial, prompting further me

86 CD39 and CD73 inhibition in preclinical and clinical studies are discussed.

87 Further animal and clinical studies are necessary to unveil the multifacete

88 Future preclinical and clinical studies are needed to determine if specific the

89 Further rigorous clinical studies are needed to determine their efficacy

90 Interventional clinical studies are needed to determine whether modific

91 However, more epidemiological and clinical studies are required for the proper validation

92 imaging coronary artery plaque, and ongoing clinical studies are testing whether there is an associa

93 Clinical studies are under way to determine if GS-9620 c

94 Clinical studies are warranted to confirm the efficacy a

95 TIEG1 has also been identified in clinical studies as one of a handful of genes whose alte

96 Tamoxifen may be suitable for clinical study as a potential treatment for diseases inv

97 phase 3 trials of pirfenidone versus placebo-Clinical Studies Assessing Pirfenidone in Idiopathic Pul

98 es of pirfenidone for IPF (the two CAPACITY [Clinical Studies Assessing Pirfenidone in IPF: Research

99 entify all English-language reports of human clinical studies assessing the safety or efficacy of FMT

100 er prospective, controlled, observer-blinded clinical study at a tertiary dermatology university hosp

101 dications, herbal medications do not require clinical studies before their marketing or formal approv

102 erature reviews, published translational and clinical studies, clinical practice guidelines, and expe

103 antly from the United States and Europe in 9 clinical studies conducted by Gilead Sciences from 2000

104 udies leading to the discovery of 31 and the clinical studies conducted with 35 that entailed the dev

105 acerbations and suggest ways in which future clinical studies could be used to find direct evidence f

106 In preliminary clinical studies, cytoplasmic localization of PELP1 was

107 hKline clinical trials were obtained through Clinical Study Data Request.

108 ociations in population-based or large-scale clinical studies demands large numbers of subjects and t

109 Recent clinical studies demonstrate oxidative stress to be pres

110 Recent clinical studies demonstrate that scopolamine, a nonsele

111 This large clinical study demonstrated that the Virtuo blood cultur

112 nt socio-economic implications, ranging from clinical study design to health care planning.

113 hts important factors to consider, including clinical study design, skin sampling, sample processing,

114 vaccine candidates including a discussion of clinical study designs, approaches to demonstrate vaccin

115 Larger-scale clinical studies, earlier application in the time course

116 In a controlled, prospective cohort clinical study, EPO administration at doses used to corr

117 Clinical studies evaluating different therapies to preve

118 will facilitate sample size calculations for clinical studies evaluating the 4-m gait speed test in a

119 There are no large clinical studies evaluating the effects of hypercapnia a

120 gents based solely, or in large part, on the clinical study experience described in published reports

121 y synthesizing findings from preclinical and clinical studies focused on sex comparisons of their the

122 ield, which is bustling with preclinical and clinical studies for not only B-cell-derived lymphoblast

123 K2982772 (compound 5), currently in phase 2a clinical studies for psoriasis, rheumatoid arthritis, an

124 3D SS-OCT possesses potential for use in clinical studies for the analysis of enamel crack behavi

125 utility of this critical cell source in pre-clinical studies for the investigation of MSC mechanisms

126 ultimodal imaging approach is recommended in clinical studies for the optimal detection and measureme

127 elding MR antagonists currently evaluated in clinical studies for the treatment of congestive heart f

128 er, the measurement of retinal blood flow in clinical studies has been challenging.

129 pan-RAF and RAF dimer inhibitor advanced to clinical study has been shown to inhibit both RAS and BR

130 This large clinical study has shown that discordance between sympto

131 combination of mouse models and correlative clinical studies, has radically improved.

132 However, experimental and clinical studies have accumulated, demonstrating that MV

133 therapy-related complications, and the first clinical studies have already been performed in the sett

134 Hundreds of clinical studies have demonstrated associations between

135 While previous pre-clinical and clinical studies have demonstrated promising proofs-of-c

136 Clinical studies have demonstrated that elevated FOXC1 e

137 Several clinical studies have evaluated the association between

138 Recent clinical studies have found a correlation between cardio

139 Clinical studies have indicated a lower abuse potential

140 Accordingly, clinical studies have pointed out an involvement of the

141 Recent epidemiological and clinical studies have reported a significantly increased

142 Recent clinical studies have reported increased inflammatory le

143 detection; however, experimental models and clinical studies have shown a complex mechanism of the e

144 Clinical studies have shown heterogeneity among EOC meta

145 Clinical studies have shown high rates of sustained viro

146 In vitro, in vivo as well as clinical studies have shown its positive effect in regul

147 Although clinical studies have shown that cell-based therapies im

148 ere or persistent pain, both preclinical and clinical studies have shown that females require two to

149 Clinical studies have shown that S. mutans is often dete

150 RATIONALE: Clinical studies have shown that Sirt3 (Sirtuin 3) expre

151 NA is immunologically subdominant to HA, and clinical studies have shown variable NA responses to vac

152 Small clinical studies have suggested that an inferior nutriti

153 Recent clinical studies have suggested that epigenetic modifica

154 Meta-analysis was planned where clinical study heterogeneity allowed.

155 effects of ES have also been demonstrated in clinical studies; however, all current studies have a la

156 nes have been implicated in experimental and clinical studies; however, immune mechanisms responsible

157 N-acetyl-L-cysteine therapy has been used in clinical studies; however, it requires doses that cause

158 Evidence from preclinical and clinical studies implicate dopamine hypofunction in the

159 ra of EMRs because it can enable large-scale clinical studies in a more time-efficient manner and imp

160 Clinical studies in ALL identified via searches of PubMe

161 There was relatively low capacity for clinical studies in developing nations.

162 We performed 2 clinical studies in healthy volunteers.

163 This rostrum reinterprets the earlier clinical studies in light of new insights and mechanisms

164 Future clinical studies in this cancer subtype should consider

165 P), the Nrf2 activator bardoxolone failed in clinical studies in type 2 diabetic patients due to card

166 ch is currently being evaluated in a phase 2 clinical study in patients with Cushing's syndrome.

167 ual variability is critical in the design of clinical studies, in the interpretation and application

168 corresponded to 35 approvals supported by 80 clinical studies included in the FDA medical officer rev

169 This was a single-center prospective clinical study including healthy heart transplant recipi

170 antages that make it particularly useful for clinical studies, including non-invasive collection, tem

171 tients who received nivolumab monotherapy in clinical studies, including phase III trials; 86 (10%) h

172 Because clinical studies indicate a correlation between the redu

173 Parallel clinical studies indicate that a similar inflammatory pa

174 Clinical studies indicate that antigen-specific antibody

175 Recent data from molecular and clinical studies indicate that hematopoiesis and leukemo

176 Preliminary clinical studies indicate that inhibition of NPM-ALK ind

177 ano-sized formulations (nanoformulations) in clinical studies indicate that our overall approach of n

178 Clinical studies indicate that thrombocytopenia correlat

179 Initial clinical studies indicated greater tau binding in AD and

180 In view of the recent experimental and clinical studies indicating a superiority of the closed-

181 In the randomized clinical study, infusion of serelaxin for 120 min increa

182 In this Review, we present the results of clinical studies investigating autologous cellular thera

183 ntiation should be taken into account by the clinical studies investigating EpAT as a risk marker and

184 linical trials, and the aging US population, clinical studies investigating improved therapeutic stra

185 s amenable to large-scale manufacturing, and clinical studies investigating the drug safety and pharm

186 nomonitoring program paralleled the ENEST1st clinical study, investigating 52 nilotinib-naive patient

187 A prospective clinical study involving 208 patients with suspected CAD

188 Recent findings from a prospective clinical study involving multiregion whole-exome sequenc

189 d translation of promising findings to large clinical studies is warranted to clearly define the effi

190 accine platform that has completed Phase III clinical studies, it is imperative to gain a better unde

191 esponse to immune therapies in ongoing human clinical studies may help identify and maximize the effe

192 ylation BeadChips has shown great utility in clinical studies, no equivalent tool is available for ro

193 Despite some promising results from clinical studies, no small molecule mGlu5 NAM has yet to

194 The human PK properties from the Phase I clinical studies of 37 were better than anticipated and

195 Further preclinical and clinical studies of AR-targeted drugs alone and in combi

196 We also summarize findings from recent clinical studies of bioelectronic neuromodulation in inf

197 However, clinical studies of dopaminergic medications, including

198 Many previous clinical studies of extracellular miRNA in archived plas

199 and underscore the critical need for larger clinical studies of fondaparinux in the treatment of sus

200 and the Bangkok MSM Cohort Study, 3 separate clinical studies of high-risk, HIV-negative persons cond

201 of circadian clock-associated molecules, and clinical studies of ketamine on plasticity-related bioma

202 y be relevant to some prior experimental and clinical studies of neutrophils.

203 ed on 44 publicly available datasets and two clinical studies of our own design, we discovered and va

204 hrine should be considered for use in future clinical studies of patients with burns and smoke inhala

205 onfirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small

206 Clinical studies of SI showed promising benefits on mild

207 d enhance the speed, validity, and ethics of clinical studies of such countermeasures?

208 Clinical studies of systemic tenofovir disoproxil fumara

209 Additional preclinical and clinical studies of the combination of nifurtimox and BS

210 sclerosis-promoting proteins in CeVD justify clinical studies of their potential value as biomarkers.

211 To date, most of the reported clinical studies of therapeutic agents have used PSMA-ta

212 bing several translational possibilities for clinical studies of vmPFC-based circuits, including neur

213 In a separate ancillary clinical study of 677 participants without primary aldos

214 To our knowledge, this is the first clinical study of a smartphone-based chloride sensor, pa

215 We report on an explorative clinical study of chronic critical illness (CCI) patient

216 cal use, our results suggest that additional clinical study of its antiproteinuric effect in glomerul

217 uires production, in quantities suitable for clinical studies, of a recombinant form that resembles f

218 Recent clinical studies on combination therapy of decitabine (D

219 We present results from clinical studies on plasma infusion done in the late 197

220 ll, these data are consistent with data from clinical studies on SGLT2 inhibitors and provide a ratio

221 modomain inhibitors and their examination in clinical studies, particularly in oncology settings, has

222 provide an overview of completed and ongoing clinical studies performed using microneedle-based techn

223 The clinical study performed using CSF and serum of MS patie

224 from genetics, tissue analyses, models, and clinical studies, points to an immune-mediated etiology

225 Although primary emphasis is given to clinical studies, preclinical investigations that are pa

226 This clinical study presents an intraindividual comparison to

227 In small clinical studies, preterm birth was associated with alte

228 g window of 80-100 min (as currently used in clinical studies) provides estimates of paired helical f

229 PubMed and the GSK Clinical Study Register were searched for suitable studi

230 uthors discuss the ethics of preclinical and clinical studies relevant to achieving an HIV cure.

231 not included due to ethical considerations; clinical study requirements imposed when PrEP was not ap

232 health applications to conduct observational clinical studies requires rigorous validation.

233 When the clinical study results were extrapolated to 4 years, the

234 nimal models, as well as a limited number of clinical studies, reveal the lipid-lowering, insulin-sen

235 The clinical study's main limitations were the relatively sm

236 Emerging clinical studies show that 'medicinal' cannabis or canna

237 BACKGROUND & AIMS: Clinical studies showed teduglutide to increase urine pr

238 gate vaccines have been tested in phase I/II clinical studies, showing promise for further developmen

239 Consistent with clinical studies, sub-RPE basal deposits were present be

240 manufacturing challenges identified in early clinical studies, such as prolonged in vitro culture, op

241 Further, human clinical studies suggest it might have a causal role in

242 Clinical studies suggest that abnormal carotid body (CB)

243 Clinical studies suggest that diets rich in omega-3 poly

244 Clinical studies suggest that intra-peritoneal (i.p.) ch

245 Initial clinical studies suggest this effect may allow transplan

246 A growing number of preclinical and clinical studies support the inflammatory hypothesis, bu

247 ase and transcriptome analysis in this pilot clinical study support the conclusion that suppression o

248 Eighty-three clinical studies supported the approval of 78 panel-trac

249 Descriptive study of clinical studies supporting panel-track supplements appr

250 eases and may serve as a platform for future clinical studies targeting allograft infection.

251 Clinical studies targeting Notch1 in a genotype-defined

252 pathology image features will be critical to clinical studies that aim to evaluate and predict treatm

253 There is clear evidence from preclinical and clinical studies that both peripheral and central sensit

254 these are underrepresented in the phase III clinical studies that established the current treatment

255 We will also examine recent preclinical and clinical studies that show significant promises of targe

256 ent evidence from multiple methodologies and clinical studies that the human anterior temporal lobe (

257 ators of iron status will allow results from clinical studies to be more meaningfully translated into

258 s of vascular access complications in future clinical studies to better inform patient and provider d

259 defects in murine HNF1A deficiency encourage clinical studies to explore the hematological consequenc

260 f computational models with experimental and clinical studies to fruitfully interrogate the immune sy

261 al collaboration will be required to perform clinical studies to inform the treatment of these rare d

262 ool developed here could be useful in future clinical studies to measure changes in CBQoL in response

263 deling must be investigated in further large clinical studies to optimize the clinical outcome of pat

264 w will discuss examples of animal models and clinical studies to provide guidance and reference for t

265 a therapeutic strategy for biomarker-driven clinical studies to treat the NSCLCs harbouring SMARCA4/

266 We performed a prospective, randomized clinical study to assess whether prophylactic treatment

267 We performed a prospective, observational clinical study to determine if ultra-widefield fluoresce

268 Such assays increase the fidelity of pre-clinical studies, to better inform lead compound develop

269 anned, step-wise sequence of preclinical and clinical studies, to determine whether this class of pot

270 In the clinical study, true positivity was significantly greate

271 Because clinical studies typically exclude these patients, their

272 appear justified, with a phase 2 randomized clinical study under way.

273 eing translated into the clinic with various clinical studies underway.

274 Among clinical studies used to support FDA approval of high-ri

275 also explain different outcomes obtained in clinical studies using CM formulas.

276 We then performed a pilot clinical study using BiliSpec to measure total bilirubin

277 However, the outcomes from preclinical and clinical studies vary, highlighting a need for a better

278 single-center, evaluator-blinded, randomized clinical study was conducted from August 13 to 15, 2014,

279 Observational clinical study was performed.

280 The goal of this clinical study was to compare the accuracy of left ventr

281 nternational, multicenter, multidisciplinary clinical study was to develop and apply a rigorous clini

282 In clinical studies, we have used PoC biochip to monitor le

283 To simulate clinical studies, we performed electroacupuncture (EA) i

284 Published clinical studies were appraised by category of evidence

285 Relevant pre-clinical and clinical studies were included and summarized.

286 or two thirds of approvals (24/35, 69%), all clinical studies were restricted to biomarker-positive p

287 When participants in the clinical study were maintained on a high sodium balance,

288 be a significant advantage in biomedical and clinical studies where untouched and unmodified cells ar

289 CTION: This is an interventional prospective clinical study which was conducted to evaluate the effic

290 ociated GBS (ZIKV-GBS) has been described in clinical studies, which may suggest a direct viral neuro

291 Clinical studies with (18)F-BMS-986192 are under way to

292 However, clinical studies with bacteria to prevent allergic disea

293 Clinical studies with broad and targeted therapeutics ha

294 kpoint in cancer, and with data of the first clinical studies with CD47-SIRPalpha checkpoint inhibito

295 Given promising early clinical studies with Minnelide, our findings suggest th

296 cer" AND "Intraoperative" AND "Margin." Only clinical studies with raw diagnostic accuracy data as co

297 A single-site prospective open-label clinical study with cyclotron-produced sodium (99m)Tc-pe

298 Nonrandomized clinical study with historical controls.

299 We next conducted a clinical study with more than 100 blond- and brown/black

300 The search was filtered to include only clinical studies written in the English language.